Latest Insights on CCI
Buy the Omicron Dip! (But Choose Wisely)
December 3, 2021 Big Picture. Big Profits., Investing
Markets went haywire this week (and last) in response to a double whammy: Omicron’s appearance on the COVID stage and a suddenly hawkish Fed. Stocks dropped across the board … but some dropped more than others. That confirms what I’ve been saying for most of 2021: The market increasingly prefers quality and consistent earnings growth […] The Perfect Recipe for a Volatile Market
December 1, 2021 Big Picture. Big Profits., Investing, Trading Strategies
Now, anyone who enjoys toiling in the kitchen has their favorite foods. For me, just about any Cajun dish will do. And in the world of Cajun cooking, you quickly learn that the “holy trinity” of onion, bell pepper and celery are the foundation for many recipes. In the same way, you need that trinity — that backbone — for a solid foundation that underpins your investment outlook. You’re in luck. You might not get to taste any of my Cajun dishes soon, but I can give you that investment foundation... Omicron’s Market Madness, Meta’s Gif Horse & Raptor’s Wreckage
November 30, 2021 Great Stuff
Don’t Panic & Carry A Towel The market gets to the bottom then goes back to the top of the slide, where it stops and it turns and it goes for a ride … ‘till it gets to the bottom and it does it again! Yeah, yeah, yeah! Do you, don’t you want me to […] Welcome to the New Normal
November 30, 2021 Investment Opportunities, Real Talk, U.S. Economy
(3-minute read) Businesses need to adapt to our constantly changing world. And I recently revealed which ones will be the winners throughout the pandemic and beyond… A Stock-Picking Mutation to Beat the Omicron Threat
November 30, 2021 Big Picture. Big Profits., Global Economy, News
This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.